3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
86
Head & Neck
12
Genitourinary
7
Thoracic
5
Breast
5
Gynecologic
4
Dermatologic
4
Tumor-Agnostic
3
Other solid neoplasm
2
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
lutetium Lu 177 dotatate
13
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
pembrolizumab
4
cabozantinib
4
Nivolumab
4
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Everolimus
3
lenvatinib
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Temozolomide
2
Phantoms, Imaging
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
toripalimab
1
tislelizumab
1
telotristat ethyl
1
surufatinib
1
peposertib
1
pazopanib
1
pasireotide
1
entrectinib
1
copper dotatate CU-64
1
atezolizumab
1
abemaciclib
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Fluorouracil
×
NET
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled